Germany Medical Devices Market Report 2026: EU MDR Compliance, DRG Reimbursement, and Hospital Procurement Intelligence

The German medical devices market is estimated at EUR 30–32 billion in 2026 — the largest medical devices market in the European Union. Germany accounts for approximately 30% of the total EU medical device market. The market is driven by a dense hospital network (1,900+ acute hospitals), high GKV reimbursement rates for approved devices, and a large installed base of diagnostic imaging and surgical equipment in both public and private hospitals. Germany is also one of the world's leading medtech manufacturing countries, home to Siemens Healthineers, B. Braun, Karl Storz, Dräger, Fresenius Medical Care, and hundreds of specialist SME manufacturers.

EU Medical Device Regulation (MDR) 2017/745 is fully enforced as of 2024, replacing the legacy MDD (93/42/EEC) directive. All Class I devices with measuring function, sterile Class I, Class IIa, IIb, and Class III devices require CE marking via an EU Notified Body assessment. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's national competent authority for medical device market surveillance and vigilance. MDR compliance timelines and Notified Body capacity constraints continue to affect the pace of product transitions. EUDAMED (European database for medical devices) registration is now mandatory. The MDR's requirements for clinical evidence, post-market clinical follow-up (PMCF), and Summary of Safety and Clinical Performance (SSCP) are more demanding than the legacy MDD standard.

Germany's hospital reimbursement system uses DRGs (Diagnosis-Related Groups) administered by InEK (Institut für das Entgeltsystem im Krankenhaus). Standard DRG payments bundle device costs within the procedure payment. For new and innovative medical technologies that exceed the standard DRG bundled cost, manufacturers can apply for NUB (Neue Untersuchungs- und Behandlungsmethoden) additional payments — providing temporary surcharge reimbursement while data is collected for full DRG integration. NUB status 1 grants additional reimbursement; NUB status 4 denies it. The NUB application process is a critical market access step for novel implants, surgical robots, and advanced diagnostics in Germany.

The five largest German medical device segments by value are: diagnostic imaging (MRI, CT, PET-CT, ultrasound — Germany is the world's largest per-capita MRI installation market); in vitro diagnostics (laboratory analysers, molecular diagnostics, point-of-care); cardiovascular devices (stents, cardiac rhythm management, TAVR/TAVI); orthopaedics and trauma (joint replacement, spinal surgery, trauma fixation — Germany has one of Europe's highest joint replacement rates); and robotic surgery and minimally invasive devices (da Vinci, Hugo, Mako systems expanding across major centres). Digital health and connected monitoring devices are the fastest-growing segment.

GKV (statutory health insurers) fund the majority of hospital device costs through DRG reimbursements. The German Hospital Federation (Deutsche Krankenhausgesellschaft, DKG) represents hospital procurement interests at national level. Individual hospital trusts and regional hospital groups negotiate device supply contracts independently or through group purchasing frameworks. University medical centres (Universitätsklinikums) — 34 in total — are the leading procurement accounts for novel and high-complexity devices. Private hospital groups (Helios Kliniken, Asklepios, Sana Kliniken, Rhön-Klinikum) manage independent procurement with centralised category management.

BioNixus supports German and European medical device manufacturers in entering and growing in GCC and MENA markets. Our services include: regulatory pathway mapping for SFDA (Saudi Arabia), MOHAP/DHA/DOH (UAE), HMC (Qatar), and all GCC competent authorities; hospital procurement intelligence at Saudi Arabia's MOH, NGHA, and private hospital networks; distributor network mapping and evaluation across all six GCC countries plus Egypt; primary research with biomedical engineers and clinical specialists; and comparative Germany vs. GCC commercial strategy analysis. BioNixus operates from London with in-country research teams across the GCC and Egypt.